China’s NMPA has granted approval to Santhera Pharmaceuticals’ AGAMREE, used in treating DMD in individuals aged four years and above.

Emerging infectious diseases necessitate rapid production of raw materials for vaccines. Strengthening domestic production and a resilient supply chain are key; advanced manufacturing facilities, like ...

Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.

Meitheal Pharmaceuticals has gained exclusive US commercial rights for XENLETA for treating CABP in the adult population.

In a new webinar, industry experts explain how innovative technology is reshaping healthcare delivery, enabling proactive interventions that improve patient outcomes, relieve NHS pressures, and pave ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.

If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

Missing and incomplete data can cause headaches for clinical trial operators; new innovations are providing an antidote.

Updated figures from the WHO show that more than one in five adults aged between 15 and 49 globally have the infection.

Lilly’s investment and the UK government’s strategic support for life sciences and healthcare represent a pivotal moment for the industry.

Er-Kim has extended its exclusive agreement with Ascendis Pharma for endocrinology treatments across multiple countries in Eurasia.